ServiziMenu principaleHome
You are here: Home > Events > Past events > 2021 > Molecular Diagnostics and Genomics in Breast Cancer

Molecular Diagnostics and Genomics in Breast Cancer

01.03.2021  -  05.03.2021



Due to the ongoing Coronavirus (COVID-19) crisis, SPCC has made the difficult decision, in agreement with the chairs and sponsors, to commute the event into a virtual meeting.
We deeply regret having to take this decision but we feel that in the current climate this was the only decision possible.
The new dates will be 1-5 March 2021.

The event attendance will be free of charge, but registration is required on www.oncocorner.net (click here)


M.S. Aapro, CH  - J. Gligorov, FR


The main common feature of cancer cells is their ability to escape to homeostatic regulation mechanisms of living. In a sense giving them immortality, causing in the absence of treatment the death of the organism, which is their origin. The exponential knowledge of the biology of cancer and the phenomenal capacity of synthesis of new treatments and diagnostic tools have opened up the prospect of a precision medicine in oncology that requires regular and frequent updating of our knowledge.
This knowledge concerns both the intrinsic prognosis of the disease, as the prediction value of therapeutic approaches that in fact becomes increasingly “personalized”. This course aims to take stock of current and future tools that help us optimize the care of patients with breast cancer.

Learning Objectives

  • Improve breast cancer patients care: value and clinical utility of prediction of CT benefit for early stage breast cancer patients
  • Practicing through case discussions


 Under the auspices of




Matti Aapro, Clinique de Genolier, Breast Center, Genolier, CH
Fabrice André, Institut Gustave Roussy, Dept. of Medical Oncology, Villejuif, FR
Anna Batistatou, University of Ioannina, Faculty of Medicine, Ioannina, GR
Francesco Cognetti, Istituto Nazionale Tumori Regina Elena, Dipartimento di Oncologia Medica, Roma, IT
Joseph Gligorov, University Cancer Institute APHP.6 Sorbonne University, Breast Cancer Expert Center, Paris, FR
Nadia Harbeck, LMU University Hospital, Breast Centre, Dept. of Obstetrics and Gynaecology, Munich, DE
Christos Markopoulos, National and Kapodistrian University of Athens, Athens, GR
Riccardo Masetti, Università Cattolica di Roma, Oncology Dpt., Roma, IT
Belinda Nedjai, Queen Mary University of London, Wolfson Institute of Preventive Medicine - Centre for Cancer Prevention, London, GB
Frederique Penault-Llorca, Centre Jean Perrin, Anatomopathology Dpt., Clermont-ferrand Cedex, FR
Giancarlo Pruneri, Fondazione IRCCS - Istituto Nazionale dei Tumori, Pathology Dpt., Milano, IT
Pascal Pujol, Centre Hospitalier Universitaire de Montpellier, Genetics Department, Montpellier Cedex5, FR
Elzbieta Senkus, Medical University of Gdansk, Dept. of Oncology and Radiotherapy, Gdansk, PL
Zsuzsanna Varga, University Hospital Zurich, Pathology Dept., Zurich, CH
Mark Verrill, Northern Centre for Cancer Care, Freeman Hospital, Medical Oncology Dept., Newcastle upon Tyne, GB
Marzia Zambon, Europa Donna - The European Breast Cancer Coalition, Milan, IT

General information


Sharing Progress in Cancer Care
Piazza Indipendenza, 2
6500 Bellinzona – Switzerland

Luis Carvalho
Luis.carvalho@spcc.net  - Tel: +41 91 820 09 58

CME Accreditation and Certificates

Participants will be issued a certificate of attendance (minimum attendance: 75% of the entire course). An online evaluation questionnaire and learning assessment test will need to be completed in order to get  the certificate that will be issued by email. 

Application for CME recognition has been submitted to the Accreditation Council of Oncology in Europe (ACOE) and 8 CME credits have been granted to this event. The American Medical Association (AMA) and the Accreditation Council for Continuous Medical Education (ACCME) designate this type of educational activity for a maximum of 1 AMA PRA category 1 credits per hour of activity.


Sharing Progress in Cancer Care wishes to extend its appreciation to Daiichi SankyoExact Sciences and Pfizer for having granted their participation and support to the Course.


The event attendance will be free of charge, but registration is required on www.oncocorner.net



01 March

15:45Welcome and introduction
Matti Aapro, CH - Joseph Gligorov, FR
15:50Optimize patient management in breast cancer: guiding adjuvant treatment decisions
Mark Verrill, UK
16:05Clinical utility of multigene assays in early breast cancer
 16:05Predictive tests
Christos Markopoulos, GR
 16:15Prognostic tests
Francesco Cognetti, IT
16:25Who to test with multigene assay: treatment algorithms – specific patient profiles (lobular; premenopausal CT decisions)
 16:25Clinical perspective
Ulrike Nitz, DE
 16:35Next Generation Sequencing. The pathology perspective.
Anna Batistatou, GR
17:00Discussion and Q&A

02 March

15:45Welcome and introduction
15:50Roundtable: Evidence based assessment of diagnostic tests: criteria for a health technology assessment – why outcomes of HTA decisions can be different…?
 15:50The French rationale
Pascal Pujol, FR
 16:00Why NICE accepted?
Mark Verrill, UK
 16:10Why German authorities accepted?
Ulrike Nitz, DE
16:20The essential pathology testing needed for breast cancer, quality control
Anna Batistatou, GR
16:40What tests to ask for and what clinical implications in "TRIPLE NEGATIVE" BrCa
Nadia Harbeck, DE
16:55The patient advocacy perspective
Marzia Zambon, IT
17:25Discussion and Q&A

03 March

17:15Welcome and introduction
17:20Group session: Patient Case discussion on multigene assays in early breast cancer: who to test and how to deal with the results?
 17:20Goup 1
Joseph Gligorov, FR - Riccardo Masetti, IT - Elzbieta Senkus, PL - Zsuzsanna Varga, CH
  Case 1: 1 patient 29 years HR+, HER2- pN0 with low-clinical risk
  Case 2: 1 patient 73 years HR+, HER2- pN1 with high-clinical risk
  Case 3: 1 patient 45 years HR+, HER2- pN0 with intermediate-clinical risk
  Case 4: 1 patient 55 years HR+, HER2- pN0 with intermediate-clinical risk
 17:20Group 2
Matti Aapro, CH - Christos Markopoulos, GR - Miguel Martin, ES - Giancarlo Pruneri, IT
  Case 1: 1 patient 29 years HR+, HER2- pN0 with low-clinical risk
  Case 2: 1 patient 73 years HR+, HER2- pN1 with high-clinical risk
  Case 3: 1 patient 45 years HR+, HER2- pN0 with intermediate-clinical risk
  Case 4: 1 patient 55 years HR+, HER2- pN0 with intermediate-clinical risk
18:35Panellists case discussion summary and Q&A

04 March

15:45Advanced breast cancer (PART1)
15:45Welcome and introduction
15:50DNA Methylation
Romano Danesi, IT
16:10NGS impact or not in breast cancer
Fabrice André, FR
16:30Alpelisib what to test
 16:30Clinical positioning
Elzbieta Senkus, PL
 16:45What to test
Frederique Penault-Llorca, FR
17:15Discussion and Q&A

05 March

15:45Advanced breast cancer (PART2)
15:45Welcome and introduction
15:50Parp inhibitors what to test
Pascal Pujol, FR
 16:05Clinical implication
Ulrike Nitz, DE
16:20Immunotherapy: what to test
Frederique Penault-Llorca, FR
 16:35Clinical implication
Francesco Cognetti, IT
16:50HER-2 alterations not defined as ASCO CAP HER-2 positivity
Frederique Penault-Llorca, FR
 17:05Clinical implication
Joseph Gligorov, FR
17:35Discussion and Q&A